Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients

Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients

Abstract Aims Hyperkalaemia is observed frequently in heart failure (HF) patients and is associated with an impaired prognosis and underuse of mineralocorticoid receptor antagonists (MRAs). However, the effects of serum potassium on prescription of the full guideline recommended daily dose of 50 mg...

Full description

Bibliographic Details
Main Authors:	Pascal R. D. Clephas, Sumant P. Radhoe, Gerard C. M. Linssen, Jorina Langerveld, Jacobus Plomp, Jeroen P. P. Smits, Michiel J. Nagelsmit, Hans‐Peter Brunner‐La Rocca, Jasper J. Brugts
Format:	Article
Language:	English
Published:	Wiley 2023-04-01
Series:	ESC Heart Failure
Subjects:	Heart failure Heart failure with reduced ejection fraction Hyperkalaemia Mineralocorticoid receptor antagonists Renin‐angiotensin‐aldosterone system inhibitors Guidelines
Online Access:	https://doi.org/10.1002/ehf2.14285

Similar Items

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
by: Josefin Henrysson, et al.
Published: (2023-02-01)

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
by: Yu F Osmolovskaya, et al.
Published: (2015-09-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial
by: Luca Monzo, et al.
Published: (2022-12-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
by: Irene Lucía Ennis, et al.
Published: (2021-01-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
by: Yuta Tezuka, et al.
Published: (2021-03-01)

Adverse Effects of Aldosterone: Beyond Blood Pressure
by: Jenifer M. Brown
Published: (2024-04-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
by: Memory MUKANGWA, et al.
Published: (2019-12-01)

Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics
by: Juan F. Delgado-Jiménez, et al.
Published: (2022-02-01)

Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners
by: Laure Abensur Vuillaume, et al.
Published: (2020-10-01)

Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
by: Shun Kohsaka, et al.
Published: (2022-09-01)

Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure
by: Ida Löfman, et al.
Published: (2018-07-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
by: Sho Suzuki, et al.
Published: (2020-10-01)

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
by: Alberto Esteban‐Fernández, et al.
Published: (2022-10-01)

Hemodynamic and hormonal actions of adrenomedullin
by: M.G. Nicholls
Published: (2004-08-01)

Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure
by: Masatake Kobayashi, et al.
Published: (2020-06-01)

Recent Advances in Remote Pulmonary Artery Pressure Monitoring for Patients with Chronic Heart Failure: Current Evidence and Future Perspectives
by: Pascal R. D. Clephas, et al.
Published: (2023-01-01)

The new Era of non-Steroidal Mineralocorticoid Antagonists in Treating Heart Failure in Diabetic Kidney Disease Patients.
by: Eqerem Hasani, et al.
Published: (2022-01-01)

Patiromer and medication optimisation in heart failure with reduced ejection fraction: a Swiss perspective
by: Philippe Meyer, et al.
Published: (2020-10-01)

Contemporary use of devices in chronic heart failure in the Netherlands
by: Anne G. Raafs, et al.
Published: (2020-08-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
by: Luo Shi, et al.
Published: (2019-11-01)

Aldosterone Excess Induced Mitochondria Decrease and Dysfunction via Mineralocorticoid Receptor and Oxidative Stress In Vitro and In Vivo
by: Cheng-Hsuan Tsai, et al.
Published: (2021-08-01)

Prognostic significance of serum potassium in patients hospitalized for acute heart failure
by: Carlo Mario Lombardi, et al.
Published: (2022-08-01)

Frequency and clinical impact of hyperkalaemia within a large, modern, real‐world heart failure population
by: Joseph B. Muhlestein, et al.
Published: (2021-02-01)

Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
by: Asadur Rahman, et al.
Published: (2023-01-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

Chronic Kidney Disease as a Comorbidity in Heart Failure
by: Magdalena Szlagor, et al.
Published: (2023-02-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
by: Ulrich Kintscher, et al.
Published: (2023-06-01)

Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post‐discharge
by: Patrick Rossignol, et al.
Published: (2020-06-01)

Heightened Cardiovascular Risk in Hypertension Associated With Renin‐Independent Aldosteronism Versus Renin‐Dependent Aldosteronism: A Collaborative Study
by: Jinbo Hu, et al.
Published: (2021-12-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
by: Takuro Abe, et al.
Published: (2020-10-01)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
by: Monarch Shah, et al.
Published: (2023-09-01)

RAAS: A Convergent Player in Ischemic Heart Failure and Cancer
by: Texali C. Garcia-Garduño, et al.
Published: (2021-07-01)

Hyperkalemia in heart failure patients: current challenges and future prospects
by: López-Vilella R, et al.
Published: (2016-02-01)

Successful management of an infant with hypertensive heart failure associated with Wilms’ tumor: a case report
by: Hiroko Miura, et al.
Published: (2020-02-01)

Invasive Devices and Sensors for Remote Care of Heart Failure Patients
by: Sumant P. Radhoe, et al.
Published: (2021-03-01)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
by: Ixchel Lima-Posada, et al.
Published: (2023-01-01)

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
by: Natalia V. Safronova, et al.
Published: (2022-01-01)